GSK said that IDRX-42 addresses all the key KIT mutations that drive tumour growth and progression in GIST, which is estimated to affect between 4,000 and 6,000 people in the US each year.

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and ... and completed a $120 million Series B last August to fund clinical development of lead cancer drug candidate IDRX-42, ...

PE Hub has rounded up six deals going back to early January involving companies in the oncology segment, starting with the ...

The British biopharmaceutical company GlaxoSmithKline Plc (GSK) is in talks to acquire the American biotech company IDRx. This is reported in a press release from GSK. The value of IDRx's assets is ...

WrestleMania is headed back to Sin City. WWE will hold WrestleMania 42 in Las Vegas at Allegiant Stadium for the second consecutive year, the company announced at Money in the Bank 2025.It will be ...